Zevra Therapeutics, Inc. (Nasdaq: ZVRA), a rare disease therapeutics company (Zevra), has announced the pricing of an underwritten public offering of 9,230,770 shares of its common stock at an offering price of US$6.50 per share, for total gross proceeds of approximately US$60 million, before deducting underwriting discounts and commissions and offering expenses payable by Zevra. All of the common stock is being offered by Zevra. The offering is expected to close on August 12, 2024, subject to customary closing conditions. In addition, Zevra has granted the underwriters a 30-day option to purchase up to an additional 1,384,615 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Latham & Watkins LLP advised Zevra in the offering with a capital markets team led by New York partners Nathan Ajiashvili and Salvatore Vanchieri, with associates Angel Marcial and Yulong Li. Advice was also provided on FDA regulatory matters by Elizabeth Richards.
Where the legal industry reads first.
Enjoyed this article? Get the biggest legal industry updates, deals, appointments, insights and expert interviews in your inbox, free.
No spam. Unsubscribe anytime.From Legal Desire
Is your firm the one being cited, or the one being skipped?
We ran the test. On several everyday legal questions, software companies are answering and law firms are not. We help firms fix that, and we build the technology behind the practice.
Lawyers and firms: get featured on Legal Desire
Share your deals, lateral moves, firm news and insights with 1M+ monthly readers: founders, law firm partners, general counsel and practising lawyers across the US, UK, EU and GCC.
Get featuredSubmit a press releaseThe advising firms, the named deal team, the value and the parties, with every other announced deal by the same firms and lawyers. Open the deal record
